FMP
ASLAN Pharmaceuticals Limited
ASLN
NASDAQ
Inactive Equity
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.
0.6 USD
-0.0999 (-16.65%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. Carl Alan Jason Morton Firth EMBA, Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://aslanpharma.comexchange
NASDAQ
Description
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was fou...
CIK
0001722926
ISIN
US04522R2004
CUSIP
04522R101
Address
83 Clemenceau Avenue
Phone
65 6222 4235
Country
SG
Employee
35
IPO Date
May 4, 2018
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
ASLN Financial Summary
CIK
0001722926
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
04522R101
ISIN
US04522R2004
Country
SG
Price
0.6
Beta
1.4
Volume Avg.
102.49k
Market Cap
1.7M
Shares
-
52-Week
0.475-17.04
DCF
0.04
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.04
P/B
-
Website
https://aslanpharma.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest ASLN News
It looks like there's no news available.
